Similarly, specific adverse events typically associated with VEGF inhibition, such as hypertension, bleeding, or thromboembolic events, did not occur more frequently in the study described here than in monotherapy studies of other VEGF inhibitors (Herbst et al, 2005) or in gemcitabine combination studies, such as a phase 2 trial of bevacizumab plus gemcitabine in advanced pancreatic cancer (Kindler et al, 2005). This evidence concerns the gene VEGFA and pancreatic neoplasm.